Evidence map›Paper›PMID 27783619›Full record

ArticlePloS one2016

The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011.

Janet Bouttell, James Lewsey, Claudia Geue, Grace Antony, Andrew Briggs, Gerry McCartney, Sharon Hutchinson, Lesley Graham, Mathis Heydtmann

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Identification of liver disease: why and how.Frontline gastroenterology · 2022
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Janet BouttellHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom.
James LewseyHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom.
Claudia GeueHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom.
Grace AntonyHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom.
Andrew BriggsHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom.
Gerry McCartneyNHS Health Scotland, Glasgow, United Kingdom.
Sharon HutchinsonSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, United Kingdom.
Lesley GrahamInformation Services Division, NHS National Services Scotland, Edinburgh, United Kingdom.
Mathis HeydtmannDepartment of Gastroenterology, Royal Alexandra Hospital, Paisley, United Kingdom.

Funding

Chief Scientist Office CZH/4/837
6 · The paper itself

Abstract

Studies assessing the costs of alcoholic liver disease are lacking. We aimed to calculate the costs of hospitalisations before and after diagnosis compared to population controls matched by age, sex and socio-economic deprivation. We aimed to use population level data to identify a cohort of individuals hospitalised for the first time with alcoholic liver disease in Scotland between 1991 and 2011.Incident cases were classified by disease severity, sex, age group, socio-economic deprivation and year of index admission. 5 matched controls for every incident case were identified from the Scottish population level primary care database. Hospital costs were calculated for both cases and controls using length of stay from morbidity records and hospital-specific daily rates by specialty. Remaining lifetime costs were estimated using parametric survival models and predicted annual costs. 35,208 incident alcoholic liver disease hospitalisations were identified. Mean annual hospital costs for cases were 2.3 times that of controls pre diagnosis (£804 higher) and 10.2 times (£12,774 higher) post diagnosis. Mean incident admission cost was £6,663. Remaining lifetime cost for a male, 50-59 years old, living in the most deprived area diagnosed with acoholic liver disease was estimated to be £65,999 higher than the matched controls (£12,474 for 7.43 years remaining life compared to £1,224 for 21.8 years). In Scotland, alcoholic liver disease diagnosis is associated with significant increases in admissions to hospital both before and after diagnosis. Our results provide robust population level estimates of costs of alcoholic liver disease for the purposes of health-care delivery, planning and future cost-effectiveness analyses.

Indexed as

Hospital CostsAdultAgedCohort StudiesDatabases, FactualFemaleHospitalizationHumansIncidenceLiver Diseases, AlcoholicMaleMiddle AgedOdds RatioPrimary Health CareScotlandSeverity of Illness Index

Identifiers

PMID27783619
PMCPMC5082635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.